Please login to the form below
RNAi
This page shows the latest RNAi news and features for those working in and with pharma, biotech and healthcare.
China backs use of Roche’s Actemra for coronavirus
The two companies are already working together on RNAi drugs against hepatitis B virus.
Latest news
-
Alnylam scores EU approval for RNAi drug Givlaari
Alnylam has claimed European Commission approval for its second RNA interface (RNAi) drug Givlaari for acute hepatic porphyria. ... Alnylam’s first RNAi drug – Onpattro (patisiran) for rare disease hereditary ATTR amyloidosis – has a similar
-
Givlaari, Rybelsus lead crowded CHMP recommendations
Leading the flurry of recommendations was Givlaari (givosiran), Alnylam’s second RNAi drug, for acute hepatic porphyria.
-
Alnylam’s third RNAi drug clears phase 3 trial in rare kidney disease
RNA interference (RNAi) drug lumasiran works upstream of the deficient enzyme, switching off production of a substrate that it converts to oxalate. ... If approved, lumasiran would be Alnylam’s third RNAi drug after Onpattro (patisiran) for
-
Sanofi narrows focus, shedding diabetes and cardiovascular research
This includes a host of investigational therapies for rare disease and cancers, such as Fitusiran (an RNAi therapeutic for haemophilia A and B), BIVV001 (a factor VIII therapy for haemophilia A)
-
FDA clears Alnylam’s second RNAi drug for rare disease
Alnylam has claimed a second US approval for one of its RNA interference (RNAi) drugs, getting an FDA nod for acute hepatic porphyria drug Givlaari. ... RNAi drugs work by switching off genes that aren’t working properly, and Givlaari is only the
More from news
Approximately 10 fully matching, plus 41 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
More than a decade of research into its RNA interference (RNAi) drugs generated the first ever approval of a drug in this category towards the end of 2018, and the company ... 2020 will be a big year as it continues its transformation into a
-
Deal Watch October 2018
Dicerna/. Lilly. GalXC RNAi technology platform for targets in Cardiometabolic disease, neurodegeneration and pain.
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
This has been Alnylam’s story over the past 16 years, as it built on Andrew Fire and Craig Mello’s Nobel prize winning discovery that naturally occurring RNAi “silences” genes, ... Its RNAi technology can be used to target any gene expressed in
-
Boosting pharma’s metabolic rate
New frontiers such as cell therapy and RNAi are becoming therapeutic realities and exciting new challenges are coming over the horizon, creating a constantly shifting landscape that leaders must navigate.
-
Deal Watch September 2016
800. Arrowhead / Amgen. Licences. 2 agreements to develop and commercialise RNAi therapies in CVS disease, upfront payments of $35m, $21.5m in equity plus $617m in option payments. ... 95. Geron / J&J. Licence. Exclusive worldwide rights to Geron's
More from intelligence
Approximately 1 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Bruce Peacock joins Dicerna from Ophthotech
Massachusetts-headquartered Dicerna develops RNAi-based therapeutics with a focus on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
-
Silence appoints chief medical officer
These studies involve Silence's investigational portfolio of RNA interference (RNAi) therapeutics, which aim to treat conditions by selectively turning off genes expressed in an individual with a certain disease.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
How do you define a biotech company?
This approach is particularly apparent in some of the recent examples of technology pioneered by biotech organisations, such as CAR-T technology (Novartis, Juno and Kite Pharma) and RNAi (Alnylam) where
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- China’s CanSino Biologics reveals phase 2 coronavirus vaccine results
- How will the events and exhibitions industry change post-Coronavirus?
- AbbVie, Roche’s Venclyxto combo reduces risk of death in first-line AML
- Eli Lilly begins COVID-19 prevention trial in nursing homes
- Russia becomes first country to approve a COVID-19 vaccine
- Tecentriq combo fails in advanced triple negative breast cancer
- UK agrees on COVID-19 vaccine deals with J&J and Novavax
- COVID-19 vaccine approval unlikely before November, says US NIH director
- Calliditas bets on PBC drug in Genkyotex buyout
- Emotion-driven clinical trial marketing: A missed opportunity?
- Speed kills
- Unleashing the Potential of Multichannel Digital Strategies in Healthcare
PMHub
McCann Health Medical Communications
We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....
Latest intelligence
- Emotion-driven clinical trial marketing: A missed opportunity?
- Whether we’re conscious of it or not, our emotions play a huge role in day-to-day decision making. Psychological scientists have long explored emotional influences on decision making. Experts like Herbert...
- Virtual Hackathon on Healthcare Innovation: a Customer Story
- How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
- OPEN Health at the World Orphan Drug Conference USA
- Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...
Quick links
Infographics
